VIRIDIAN THERAPEUTICS INC

NASDAQ: VRDN (Viridian Therapeutics, Inc.)

最近更新时间: 17小时之前

29.84

0.04 (0.13%)

前收盘价格 29.80
成交量 1,147,715
价格/销量 (P/S) 122.57
股市价格/股市净资产 (P/B) 7.26
52周波幅
13.18 (-55%) — 34.29 (14%)
营业利益率 (TTM) -130,369.45%
稀释每股收益 (EPS TTM) -3.35
总债务/股东权益 (D/E MRQ) 3.82%
流动比率 (MRQ) 19.49
营业现金流 (OCF TTM) -279.75 M
杠杆自由现金流 (LFCF TTM) -171.41 M
资产报酬率 (ROA TTM) -32.62%
股东权益报酬率 (ROE TTM) -51.95%

AIStockmoo 评分

0.9
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
资本回报低于资本成本。资本回报上升。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年呈下降趋势。股价略低于52周高点。 参考
股价与均线呈多头排列。主要均线向上。接近上升的均线。上涨日成交量较大。 参考
K线形态 参考 NA
高于中期趋势线。 参考
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
内部交易活动 参考 NA
机构在最新13F申报中净+3.87%的股份:136家增持,88家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-12.7%,回补天数9.1天(FINRA)。 参考
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
股价高于其52周平均水平。5年来上涨。 参考
短、中、长期趋势均向上。短期动能上升。 参考
股价接近阻力位。 参考
最终评分 0.87
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Viridian Therapeutics, Inc. 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B
VRDN - - - 7.26
TRML 1 B - - 4.76
OBIO - - - 57.25
VRCA - - - 15.60
TECH - 0.44% - 5.28
ABEO - - - 1.10

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 0.16%
机构持股比例 114.61%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 126.23%

持仓变动 机构数 股数
增持 136 20,191,430
减持 88 17,420,004
新建仓 45 7,039,728
清仓 25 5,397,253

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 17,042,236 9.1
15 Oct 2026 18,002,311 8.0
30 Sep 2026 17,965,668 8.9
15 Sep 2026 19,465,251 15.7
31 Aug 2026 19,511,841 16.6
14 Aug 2026 19,026,492 9.1

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

8 正面 1 负面 3 中性
日期 类型 细节
09 Nov 2026 Yahoo Finance Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
Jefferies sees VRDN-008 as a potential best-in-class FcRn inhibitor, with its extended half-life supporting eight-week dosing and offering a competitive advantage in a market dominated by less convenient treatment schedules. The broker views Viridian Therapeutics (NASDAQ:VRDN)'s decision to…
09 Nov 2026 Yahoo Finance Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
WALTHAM, Mass., November 09, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008…
07 Nov 2026 Yahoo Finance Viridian Therapeutics Inc (VRDN) (Q3 2026) Earnings Call Highlights: Lumvoa's Strong Debut With ...
Viridian Therapeutics Inc (VRDN) kicked off its Lumvoa launch with more than 100 patients treated and over $955 million in cash to fund operations through profitability.
06 Nov 2026 Yahoo Finance Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
WALTHAM, Mass., November 06, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present…
06 Nov 2026 Yahoo Finance Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
04 Nov 2026 Yahoo Finance Viridian Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Viridian Therapeutics, Inc.'s Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance Viridian Therapeutics (VRDN) Stock Looks Overvalued Even With Its New Launch
Viridian Therapeutics has had a powerful three year run, yet the real puzzle for investors is whether the current share price still lines up with what its balance sheet supports. With fresh product launches and pipeline progress now in the mix, the question is how far the stock has moved relative…
04 Nov 2026 Yahoo Finance What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics (NASDAQ:VRDN) reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment’s first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30. President and CEO Steve Mahoney said the launch exceeded t…
04 Nov 2026 Yahoo Finance Viridian (VRDN) Q3 2026 Earnings Call Transcript
First full quarter of Lumvoa sales beat expectations as patient starts accelerated.
04 Nov 2026 Yahoo Finance Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +19.80% and +348.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
04 Nov 2026 Yahoo Finance Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
WALTHAM, Mass., November 04, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the…
02 Nov 2026 Yahoo Finance A $2 Billion Fund Bought These 3 Stocks Last Quarter
Key TakeawaysA $2 billion fund’s latest 13F shows its three biggest adds in the quarter ended June 30 were Viridian Therapeutics, Travere Therapeutics, and Legend Biotech. Analysts’ average price targets sit 47% to 111% above Friday’s close for the three stocks.
27 Oct 2026 Yahoo Finance How FDA Approval Will Impact Viridian Therapeutics Stock
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, an IGF-1R antibody for active and chronic Thyroid Eye Disease, following Phase III data showing meaningful clinical benefits with a 12-week, 5-infusion IV regimen. The approval gives Viridian Therapeutics its first commercial…
20 Oct 2026 Yahoo Finance Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
WALTHAM, Mass., October 20, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial…
16 Oct 2026 Yahoo Finance Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics has seen a mixed share price story in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$19.03 price tag adequately grounded in what the company is generating through its sales? Over the past 3 years the stock has…
22 Sep 2026 Yahoo Finance Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark…
02 Sep 2026 Yahoo Finance Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside…
显示更多

近期信号 K线形态与EMA交叉

▲ 黄金交叉 17个交易日前 · 23 Oct
长期 · EMA 50/200
50日EMA上穿200日EMA,是广受关注的长期趋势转为向上的信号。

技术形态 中期

趋势排列
斜率
入场位置
成交量
股价与均线呈多头排列。主要均线向上。接近上升的均线。上涨日成交量较大。
最近支撑: 29.41 – 31.12 · 强
最近阻力: 31.30 – 31.96 · 中等

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票